RHOA G17V与p300结合增强其组蛋白乙酰转移酶活性:TFH淋巴瘤表观遗传失调的新机制
研究在稳定表达RHOA G17V和/或CD28 T195P的Jurkat T细胞系及4例携带RHOA G17V与4例野生型RHOA的AITL肿瘤样本中,发现RHOA G17V与CD28 T195P共表达时IL-2产生及NFAT、AP1转录活性显著高于任一单突变;p300为RHOA G17V主要互作伙伴,p300抑制可消除IL-2分泌增加,RHOA G17V细胞中p300特异性H3K18ac和H3K27ac标记增加。
要点
- RHOA G17V与CD28 T195P共表达时IL-2产生及NFAT、AP1转录活性显著高于任一单突变。
- p300是RHOA G17V的主要互作伙伴,p300抑制可消除CD3/CD28刺激诱导的IL-2分泌增加。
- 携带RHOA G17V的AITL肿瘤细胞H3K18ac和H3K27ac水平高于非肿瘤性T细胞。
核心结论
- RHOA G17V通过增强p300组蛋白乙酰转移酶活性来增强CD28 T195P诱导的NFAT和AP1转录活性,扩展了表观遗传失调参与TFH淋巴瘤发病机制的认识。
研究设计与样本
- 研究生成稳定表达野生型RHOA或RHOA G17V与野生型CD28或CD28 T195P的Jurkat T细胞系,并使用4例携带RHOA G17V和4例携带野生型RHOA的AITL患者肿瘤样本进行免疫荧光染色。
主要发现
- 在激动性抗CD3和抗CD28抗体激活T细胞后,RHOA G17V与CD28 T195P共表达诱导的IL-2产生水平及NFAT和AP1转录活性显著高于任一单突变。
- 在模型和人类原代T细胞中,p300被鉴定为RHOA G17V的主要互作伙伴;p300抑制消除了表达RHOA G17V和/或CD28 T195P的细胞中CD3/CD28刺激诱导的IL-2分泌增加。
- 染色质免疫沉淀和免疫荧光染色显示,表达RHOA G17V的细胞中IL-2启动子处p300特异性H3K18ac标记增加,全基因组H3K27ac标记增加。
- 对4例携带RHOA G17V变异的AITL和4例携带野生型RHOA的AITL患者肿瘤样本免疫荧光染色显示,携带RHOA G17V的肿瘤性TFH细胞H3K18ac和H3K27ac水平高于非肿瘤性T细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The RHOA G17V mutation is highly recurrent in T follicular helper (TFH) cell lymphoma of the angioimmunoblastic type (AITL; 60%-70% of cases) and frequently associated with mutations in other T-cell receptor signaling genes, including CD28. Here, we sought to elucidate how RHOA and CD28 variants may work in concert to sustain T-cell activation by generating stable Jurkat T-cell lines expressing wild-type (wt) RHOA or RHOA G17V with wt CD28 or CD28 T195P. Concomitant expression of RHOA G17V and CD28 T195P induced significantly higher levels of interleukin-2 (IL-2) production and NFAT nuclear factor of activated T cells (NFAT) and activator protein 1 (AP1) transcriptional activities than either variant alone upon T-cell activation with agonistic anti-CD3 and anti-CD28 antibodies. We identified the histone acetyltransferase p300 as a major interacting partner of RHOA G17V in our model and human primary T cells. p300 inhibition abolished the increased IL-2 secretion induced by CD3/CD28 stimulation in cells expressing RHOA G17V and/or CD28 T195P. Chromatin immunoprecipitations and immunofluorescence staining revealed an increase of p300-specific H3K18ac and H3K27ac marks at the IL-2 promoter and across whole genome, respectively, in cells expressing RHOA G17V. Finally, immunofluorescence staining of tumor samples from 4 patients with AITL carrying RHOA G17V variant and 4 carrying wt RHOA showed that neoplastic TFH cells with RHOA G17V have increased H3K18ac and H3K27ac levels compared with non-neoplastic T cells. Collectively, these findings uncover a new mechanism of action by which RHOA G17V potentiates CD28 T195P-induced NFAT and AP1 transcriptional activities by enhancing p300 histone acetyltransferase activity and expand the notion that epigenetic deregulation contributes to the pathogenesis of TFH lymphomas.
引用
- Vallois D, Juilland M, Ioannidou K, et al. Binding of RHOA G17V to p300 enhances its HAT activity: a new mechanism of epigenetic deregulation in TFH lymphoma. Blood Adv. 2025. PMID: 40020168. doi:10.1182/bloodadvances.2024014671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。